This Week in PLoS

In PLoS One this week, MIT researchers say they've developed the first ever broad-spectrum antiviral therapeutic. Instead of taking a pathogen-specific approach to developing antivirals, the team has created a new approach, called Double-Stranded RNA Activated Caspase Oligomerizer, or DRACO, which selectively induces apoptosis in cells that contain viral dsRNA, and kills infected cells without harming normal cells.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.